Ovarian cancer
Start with the big picture
Most ovarian cancers are epithelial and are diagnosed at an advanced stage. Because general-population screening is not recommended, surveillance is focused on people at high risk, including those with BRCA1/2 mutations or Lynch syndrome; CA-125 is nonspecific and is considered alongside transvaginal ultrasound in this setting. FIGO stage guides initial management, which commonly involves cytoreductive surgery and systemic chemotherapy. The lesson outlines carboplatin–paclitaxel treatment, selected use of bevacizumab, and PARP-inhibitor maintenance, including important adverse effects and monitoring. For recurrence, the interval since platinum treatment distinguishes platinum-sensitive from platinum-resistant disease and helps guide regimen selection.
What you'll learn
- Describe why ovarian cancer commonly presents at an advanced stage.
- Identify high-risk groups and explain the role and limits of surveillance.
- Relate FIGO staging and surgical resectability to initial treatment planning.
- Recognize key uses and monitoring concerns for systemic and maintenance therapies.
- Distinguish platinum-sensitive from platinum-resistant recurrent disease.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
